U.S. Antitrust Litigation Concerning Licensed Gatifloxacin Ophthalmic Solution
First written in FY2017-Q3. 4 of 6 entries say "Restated". Latest entry: FY2019.
The whole theme swung hardest in 2018: 2 of 8 companies on the "Worse" side.
1 other company's latest entry also says "Dropped".
- FY2019DroppedAnnual report
「The Group may face lawsuits concerning patents, product liability under the PL Act, antitrust law, environmental protection, labor matters and other issues arising in its business activities.」
The description of settlement-related costs for the individual gatifloxacin litigation was not repeated in this filing and is presented as a general litigation risk. - FY2018RestatedAnnual report
「Approximately ¥400 million in settlement-related costs from the U.S. antitrust class action alleging violations concerning the licensed product, gatifloxacin ophthalmic solution」
Approximately ¥400 million in settlement-related costs from the U.S. class action concerning gatifloxacin ophthalmic solution continues to be disclosed as an extraordinary loss. - FY2018-Q3RestatedAnnual report
「Approximately ¥400 million in settlement-related costs from the class action alleging violations of U.S. antitrust law concerning the licensed product, gatifloxacin ophthalmic solution, was recorded as an extraordinary loss.」
Approximately ¥400 million in settlement-related costs from the U.S. antitrust class action concerning gatifloxacin ophthalmic solution was recorded as an extraordinary loss. - FY2018-Q2RestatedAnnual report
「Approximately ¥400 million in settlement-related costs from the class action alleging violations of U.S. antitrust law concerning the licensed product, gatifloxacin ophthalmic solution, was recorded as an extraordinary loss.」
Approximately ¥400 million in settlement-related costs from the U.S. antitrust class action concerning gatifloxacin ophthalmic solution was recorded as an extraordinary loss. - FY2017RestatedAnnual report
「¥1,025 million in settlement-related costs from litigation alleging violations of U.S. antitrust law concerning the licensed product, gatifloxacin ophthalmic solution」
The settlement of the litigation concerning gatifloxacin ophthalmic solution and the recognition of ¥1,025 million in costs are recorded as full-year results. - FY2017-Q3MaterialisedAnnual report
「Approximately ¥1 billion in settlement-related costs relating to litigation alleging violations of U.S. antitrust law concerning the licensed product gatifloxacin ophthalmic solution was recorded as an extraordinary loss.」
The U.S. antitrust litigation concerning gatifloxacin ophthalmic solution was settled, and approximately ¥1 billion in settlement-related costs was recorded as an extraordinary loss.